Blueprint Medicines Corp (BPMC) Insider Trading
- $348,278.00
- $152,874,979.57
- March 28, 2024
- Jeffrey W Albers
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| March 28, 2024 | CFO | 5,000 | $95.00 | Sell | $475,000.00 | |
| March 20, 2024 | Director | 25,073 | $87.28 | Sell | $2,188,371.44 | |
| March 15, 2024 | CFO | 13,734 | $87.78 | Sell | $1,205,570.52 | |
| March 7, 2024 | CEO | 12,464 | $90.69 | Sell | $1,130,360.16 | |
| March 7, 2024 | COO | 6,070 | $90.69 | Sell | $550,488.30 | |
| March 7, 2024 | Insider | 3,097 | $90.69 | Sell | $280,866.93 | |
| March 7, 2024 | CFO | 5,003 | $90.69 | Sell | $453,722.07 | |
| March 7, 2024 | EVP | 5,194 | $90.69 | Sell | $471,043.86 | |
| March 4, 2024 | Insider | 621 | $93.65 | Sell | $58,156.65 | |
| Feb. 28, 2024 | Insider | 5,000 | $100.00 | Sell | $500,000.00 | |
| Jan. 25, 2024 | Director | 25,000 | $81.91 | Sell | $2,047,750.00 | |
| Dec. 22, 2023 | Insider | 714 | $90.00 | Sell | $64,260.00 | |
| Dec. 7, 2023 | Insider | 5,000 | $75.00 | Sell | $375,000.00 | |
| Dec. 4, 2023 | Insider | 600 | $71.43 | Sell | $42,858.00 | |
| Nov. 30, 2023 | Director | 5,000 | $70.55 | Sell | $352,750.00 | |
| Nov. 24, 2023 | Director | 15,000 | $67.51 | Sell | $1,012,650.00 | |
| Nov. 3, 2023 | Director | 1,485 | $60.13 | Sell | $89,293.05 | |
| Nov. 1, 2023 | Director | 3,881 | $60.02 | Sell | $232,937.62 | |
| Oct. 26, 2023 | Insider | 600 | $56.40 | Sell | $33,840.00 | |
| Oct. 4, 2023 | Insider | 3,769 | $48.06 | Sell | $181,138.14 | |
| Sept. 28, 2023 | Director | 6,898 | $50.17 | Sell | $346,072.66 | |
| Aug. 25, 2023 | Director | 10,000 | $50.16 | Sell | $501,600.00 | |
| June 5, 2023 | Insider | 2,307 | $52.06 | Sell | $120,102.42 | |
| March 6, 2023 | Director | 9,793 | $45.67 | Sell | $447,246.31 | |
| March 6, 2023 | Insider | 1,875 | $45.68 | Sell | $85,650.00 | |
| March 6, 2023 | COO | 3,059 | $45.67 | Sell | $139,704.53 | |
| March 6, 2023 | EVP | 3,322 | $45.68 | Sell | $151,748.96 | |
| March 6, 2023 | CFO | 3,007 | $45.68 | Sell | $137,359.76 | |
| March 6, 2023 | CEO | 6,640 | $45.69 | Sell | $303,381.60 | |
| Dec. 5, 2022 | Director | 20,000 | $50.09 | Sell | $1,001,800.00 | |
| Nov. 3, 2022 | CEO | 1,100 | $43.98 | Buy | $48,378.00 | |
| Nov. 3, 2022 | COO | 533 | $45.24 | Sell | $24,112.92 | |
| Oct. 4, 2022 | Insider | 3,477 | $67.30 | Sell | $234,002.10 | |
| Aug. 24, 2022 | Insider | 5,000 | $75.11 | Sell | $375,550.00 | |
| Aug. 22, 2022 | Director | 8,410 | $70.54 | Sell | $593,241.40 | |
| Aug. 19, 2022 | Director | 1,590 | $70.02 | Sell | $111,331.80 | |
| Aug. 16, 2022 | Director | 20,000 | $68.41 | Sell | $1,368,200.00 | |
| Aug. 8, 2022 | Director | 10,000 | $70.07 | Sell | $700,700.00 | |
| Aug. 4, 2022 | SVP | 2,500 | $60.44 | Sell | $151,100.00 | |
| June 6, 2022 | Insider | 1,908 | $59.76 | Sell | $114,022.08 | |
| April 6, 2022 | CEO | 5,000 | $70.11 | Sell | $350,550.00 | |
| March 16, 2022 | Insider | 2,219 | $60.00 | Sell | $133,140.00 | |
| March 10, 2022 | Insider | 2,339 | $57.15 | Sell | $133,673.85 | |
| March 7, 2022 | Insider | 256 | $56.19 | Sell | $14,384.64 | |
| March 3, 2022 | Director | 5,000 | $59.98 | Buy | $299,900.00 | |
| March 3, 2022 | Insider | 761 | $60.27 | Sell | $45,865.47 | |
| Dec. 15, 2021 | Insider | 729 | $100.00 | Sell | $72,900.00 | |
| Dec. 13, 2021 | COO | 1,000 | $98.30 | Sell | $98,300.00 | |
| Dec. 7, 2021 | EVP | 5,000 | $97.30 | Sell | $486,500.00 | |
| Nov. 15, 2021 | CEO | 30,000 | $114.50 | Sell | $3,435,000.00 |
Insiders are both buying and selling Blueprint Medicines Corp stock.
The insider traders at Blueprint Medicines Corp are: Jeffrey W Albers, Ariel Hurley, Kate Haviland, Daniel Lynch, Christopher K Murray, Marion Dorsch, George Demetri, Nicholas Lydon, Anthony L Boral, Tracey L Mccain, Fmr Llc, L. Becker Hewes, Christina Rossi, Christoph Lengauer, Michael Landsittel, Mark Alan Goldberg, Fouad Namouni, Debra Durso-Bumpus, Charles A Rowland Jr, Percy H Carter, Kevin P. Starr, Rock Ventures Ii L.P. Third, Lonnel Coats, Alexis Borisy, and Mark J Levin
The most active insider trader at Blueprint Medicines Corp is Jeffrey W Albers with 38 trades.
Rock Ventures Ii L.P. Third has sold the most Blueprint Medicines Corp stock with a total value of $70,560,000.00.
Mark Alan Goldberg has bought the most Blueprint Medicines Corp stock with a total value of $599,800.00.
The most recent insider trade for Blueprint Medicines Corp was on March 28, 2024.
The single biggest insider buy for Blueprint Medicines Corp was from Mark Alan Goldberg with a total value of $299,900.00 on March 3, 2022.
The single biggest insider sell for Blueprint Medicines Corp was from Rock Ventures Ii L.P. Third with a total value of $35,280,000.00 on Feb. 7, 2017.